Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — J.P. Morgan Healthcare Conference 2018
17 slides from Angiodynamics's conference presentation, Jan 10, 2018
Slide 1: J.P. Morgan Healthcare Conference – AngioDynamics Investor Presentation
J.P. Morgan Healthcare Conference – AngioDynamics Investor Presentation January 10, 2018
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash fl
Slide 3: AngioDynamics Today
AngioDynamics Today 3 Focus on serving undertreated patient populations, improving patient outcomes and offering economic value to healthcare providers Operating franchises in growing, strategic markets Growth strategy to optimize product portfolio, focus on operational efficiencies and expand inter
Slide 4: Growth through Focus, Execution, Accountability
Growth through Focus Execution Accountablity ® angiodynamics
Slide 5: AngioDynamics' Framework For Growth
AngioDynamics’ Framework For Growth Driving Efficiencies Investing in Disruptive Technology Strengthening Global Platform Driving Performance Delivering sustainable and improved margins Focused investments on growth and innovation Increased focus in high growth markets Strong cash flow generation
Slide 6: 2017: Strengthening Operations; 2018: Driving Transformation
2017: Strengthening Operations More disciplined Product Development process Defined and implemented a new corporate strategy Commercial Improvements Revised compensation structure to align to industry best practices Operational Improvements Improved our supply chain Simplified our footprint Strength
Slide 7: Three Global Business Units with Unique Growth Opportunities
Three Global Business Units with Unique Growth Opportunities CategoriesFluid ManagementVenous InsufficiencyThrombus ManagementDrainageAngiographic CathetersKey Growth Drivers Peripheral Vascular Vascular Access Oncology/Surgery CategoriesPICCsPortsDialysisKey Growth Drivers CategoriesNon-Thermal Abl
Slide 8: Strengthening Clinical Evidence
Strengthening Clinical Evidence Peripheral Vascular Vascular Access Oncology/Surgery More than 300 articles published to date. Additional research is being collected across disease states 6 research studies ongoing 6 peer reviewed articles published Enrollment completed in perforator (Secure) trial
Slide 9: Financial Update
Financial Update >) angiodynamics
Slide 10: FY 2018 Six-Month Actuals and Full-Year Expectations
FY2018First Half Results FY2018FY Expectations Revenue $172.1M $345M – $350M GAAP Earnings Per ShareNon-GAAP Adjusted EPS† $0.01$0.28 $0.00 – $0.04$0.64 – $0.68 Gross Margin 48.8% ~52% Adjusted EBITDAS† $24.6M $55M+ Free Cash Flow $12.0M $30M - $35M* Cash and Cash Equivalents $49.9M $50M+ Debt $95.0
Slide 11: FY 2018 Gross Margin Walk
FY2018 FY 2018 First-Half Gross Margin $48.8% Price (50 bps) Volume 70 bps Royalty 80 bps Revaluation of standard cost 170 bps Plant consolidations 170 bps Inventory provision for discontinued product 100 bps Acculis to Solero transition 40 bps Other (OH Reduction, Freight Expense) 30 bps FY 2018 Se
Slide 12: FY 2018 Tax Reform Act Impact – Adjusted EPS Impact
FY 2018 Tax Reform Act Impact – Adjusted EPS Impact FY2018 Adjusted EPS Pre-Tax Reform Current Statutory Tax Rate 36%* Adjusted Net Income $24 – 26M Non-GAAP Adjusted EPS range $0.64-$0.68 FY2018 Adjusted EPSPost-Tax Reform Tax Reform Act Impact 214 Days before Enactment 36%* 151 Days post Enactment
Slide 13: FY 2018 Tax Reform Act Impact – Cash Taxes and NOLs
FY 2018 Tax Reform Act Impact – Cash Taxes and NOL’s $ in millions Federal Net Operating Losses $155-$165m US GAAP Taxes Effective GAAP Tax Rate Cash Taxes Effective Cash Tax Rate FY2018 FY2019 FY2020 Federal income tax rate reduction (35% to 21%): Ample Federal net operating losses, therefore, rate
Slide 14: Significant Liquidity Drives Capital Allocation Strategy
Significant Liquidity Drives Capital Allocation Strategy Uses of Cash Priorities Invest internallyOpportunistically evaluate M&AExecute share buyback program authorized up to $25 million Significant cash generation and available debt capital support range of allocation options to capitalize on growt
Slide 15: Our Vision for AngioDynamics
Our Vision for AngioDynamics 3 1 2 Increase our value to each of our stakeholders Partner with providers and caregivers to deliver superior care to patients Be recognized as a consistent, high-performing MedTech company
Slide 16: Reconciliation Tables
Reconciliation Tables ié >) angiodynamics
Slide 17: Reconciliation of Net Income to Adjusted Net Income and Adjusted EBITDAS
Reconciliation of Net Income to non-GAAP Adjusted Net Income: Reconciliation of Net Income to EBITDAS and Adjusted EBITDAS: ‘Three months ended ‘Six months ended Three months ended ‘Six months ended ‘November 30, November 30, ‘November 30, November 30, November 30, November 30, ‘November 30, Novembe
AngioDynamics — J.P. Morgan Healthcare Conference 2018 on 6ix